Shares of Lupin surged nearly 2% following the announcement by the drug maker Lupin Ltd on Tuesday (April 9) that it has launched the first generic version of Oracea (doxycycline capsules, 40 mg) in the United States.
According to a regulatory filing by Lupin, the business achieved this noteworthy milestone following the product’s approval by the US Food and Drug Administration (US FDA).
According to Lupin, adult patients’ inflammatory lesions (papules and pustules) caused by rosacea can be treated with 40 mg capsules of doxycycline.
As of 10:00 am the shares were trading at ₹1,622.00 on NSE
The company added that as of February 2024, 40 mg doxycycline capsules were expected to have sold $128 million annually in the US market.